Erzhi pills reverse PD-L1-mediated immunosuppression in melanoma microenvironment
Background: Cancer immunotherapies aimed at activating immune system, especially by blocking immune checkpoints, have become a successful modality for treating patients with advanced cancers. However, its clinical practice is frequently conceded by high outcomes, low initial response rates and sever...
Main Authors: | Zhirui Fang, Yuejin Xue, Yuze Leng, Lusha Zhang, Xiuyun Ren, Ning Yang, Jing Chen, Lu Chen, Hong Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-02-01
|
Series: | Heliyon |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844024010193 |
Similar Items
-
Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy
by: Katarzyna Tomela, et al.
Published: (2023-03-01) -
Real world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma
by: Ronen Stoff, et al.
Published: (2023-05-01) -
Exchangeable Zinc Pool Size Reflects Form of Zinc Supplementation in Young Children and Is Not Associated with Markers of Inflammation
by: Julie M. Long, et al.
Published: (2022-01-01) -
LAG3-PD1 or CTLA4-PD1 Inhibition in Advanced Melanoma: Indirect Cross Comparisons of the CheckMate-067 and RELATIVITY-047 Trials
by: Bai-Wei Zhao, et al.
Published: (2022-10-01) -
Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma
by: Jesper Geert Pedersen, et al.
Published: (2022-07-01)